GlassScriptPhysician profile
Xudong Xu
NPI 1992701908
$32,631.57
in general payments reported to CMS, 2019-2025
52 companies · $4,863 in 2025
The $4,863 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,143 · 2020: $3,144 · 2021: $3,611 · 2022: $4,291 · 2023: $4,397 · 2024: $5,182 · 2025: $4,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,379.24 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,525.31 | 2019-2025 | Vemlidy, Livdelzi |
| Astrazeneca Pharmaceuticals LP | $5,919.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,975.30 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $1,875.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,597.27 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $1,167.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,144.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $1,127.51 | 2019-2024 | Verquvo, Capvaxive, Steglatro |
| Amarin Pharma, INC. | $1,072.55 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $1,062.19 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $946.49 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $847.53 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $739.52 | 2020-2025 | Linzess, Creon, Viberzi |
| Nestle Healthcare Nutrition INC. | $551.61 | 2021-2023 | |
| Madrigal Pharmaceuticals | $521.95 | 2024-2025 | Rezdiffra |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xudong Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.